Is SARS-CoV-2 infection an emerging risk factor for splanchnic venous thrombosis?

CONCLUSIONS: Our study warns the clinicians to maintain a high index of suspicion for thrombosis in patients diagnosed with SARS-CoV-2 infection manifesting gastrointestinal symptoms. An appropriate diagnostic work-up could allow to obtain an early diagnosis and consequently improve the clinical outcome of patients.PMID:34511494 | DOI:10.3233/CH-211256
Source: Clinical Hemorheology and Microcirculation - Category: Hematology Authors: Source Type: research

Related Links:

AbstractCardiovascular (CV) engagement in coronavirus disease 2019 (COVID-19) is a huge determinant of prognosis during the acute phase of the disease. However, little is known about the potential chronic implications of the late phase of COVID-19 and about the appropriate approach to these patients. Heart failure, type 1 and type 2 myocardial infarction, arrhythmias, myocarditis, pulmonary fibrosis, and thrombosis have been shown to be related to severe acute respiratory syndrome coronavirus 2 infection, and a ‘long COVID-19’ illness has been recognized with fatigue, chest pain, and dyspnoea among the most fre...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: ESC and HFA Paper Source Type: research
In conclusion, the studies promoting mAB therapy in COVID-19 are very promising but the results are not yet definitive and more investigations are needed to certify both their good neutralizing effects of SARS-CoV-2, and to eliminate, or at least mitigate, the harmful side effects.PMID:33904269 | DOI:10.23812/Conti_Edit_35_2_1
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Authors: Source Type: research
NEW BRUNSWICK, N.J., April 23, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company’s COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combina...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
Khalid J Alzahrani Aristóteles Góes-Neto Vasco Azevedo Preetam Ghosh Debmalya Barh The COVID-19 pandemic has infected millions worldwide, leaving a global burden for long-term care of COVID-19 survivors. It is thus imperative to study post-COVID (i.e., short-term) and long-COVID (i.e., long-term) effects, specifically as local and systemic pathophysiological outcomes of other coronavirus-related diseases (such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS)) were well-cataloged. We conducted a comprehensive review of adverse post-COVID health outcomes and ...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
We reported a case of a 49-year-old man infected with COVID-19, presenting with fever, chest pain, limb weakness, myalgia, and dyspnea. The patient was diagnosed with severe COVID-19 pneumonia, pulmonary thromboembolism (PTE), deep vein thrombosis (DVT), and cerebral infarction. He received supportive and empirical treatment including anticoagulant treatment, anti-inflammatory treatment, oxygen supply, and inhalation therapy. The patient's symptoms, CT images, and laboratory results improved after treatment, and a throat swab was reported to be negative for SARS-CoV-2 virus by polymerase chain reaction (PCR) test. However,...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Coronavirus | COVID-19 | Gastroenterology | Hematology | Pain | Pulmonary Thromboembolism | SARS | Study | Thrombosis